Table 3 Patients’ perception of prevention of transmission of COVID-19 stratified by patient characteristics^a

Age (years), n (%)

 < 0.001

0–15

577

(93.4)

41

(6.6)

16–64

839

(86.5)

131

(13.5)

65–74

71

(82.6)

15

(17.4)

 > 74

117

(91.4)

11

(8.6)

Diagnosis category, n (%)

Infectious and parasitic diseases

304

(87.9)

42

(12.1)

Endocrine, nutritional, and metabolic diseases

15

(100.0)

0

(0.0)

Mental and behavioral disorders

6

(75.0)

2

(25.0)

Diseases of the nervous system

25

(80.6)

6

(19.4)

Diseases of the ear and mastoid process

28

(90.3)

3

(9.7)

Diseases of the circulatory system

15

(88.2)

2

(11.8)

Diseases of the respiratory system

912

(92.6)

73

(7.4)

Diseases of the digestive system

63

(81.8)

14

(18.2)

Diseases of the skin and subcutaneous tissue

31

(79.5)

8

(20.5)

Diseases of the musculoskeletal system and connective tissue

35

(68.6)

16

(31.4)

Diseases of the genitourinary system

56

(87.5)

8

(12.5)

Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified

49

(79.0)

13

(21.0)

Injury, poisoning, and other certain consequences of external causes

59

(85.5)

10

(14.5)

Other

6

(85.7)

1

(14.3)

Symptom severity, n (%)

Mild

898

(91.6)

82

(8.4)

Moderate

680

(86.7)

104

(13.3)

Severe

26

(68.4)

12

(31.6)

Personal protective equipment used

895

(92.7)

70

(7.3)

Diagnostic tools for COVID-19 used

439

(97.3)

12

(2.7)

Time of medical examination (minutes), mean (SD)

30.1

(14.3)

27.2

(12.3)

Time of medical examination (minutes), n (%)

 < 15

234

(84.8)

42

(15.2)

16–25

554

(88.6)

71

(11.4)

 ≥ 26

816

(90.6)

85

(9.4)